Minutia
1 known investors
Minutia develops insulin-producing cell transplants that can be monitored in vivo over time, aimed at improving cell replacement therapy for diabetes. The company works in the regenerative medicine and cell therapy field.
Investors · 1
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $870K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $300K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Minutia do?
- Minutia develops insulin-producing cell transplants that can be monitored in vivo over time, aimed at improving cell replacement therapy for diabetes. The company works in the regenerative medicine and cell therapy field.
- Who are Minutia's investors?
- Minutia's investors include BioBrit.